摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

nicotinium hydrochloride | 1087716-08-2

中文名称
——
中文别名
——
英文名称
nicotinium hydrochloride
英文别名
nicotine dihydrochloride;nicotine hydrochloride;Nicotin-hydrochlorid;hydron;3-(1-methylpyrrolidin-2-yl)pyridine;chloride
nicotinium hydrochloride化学式
CAS
1087716-08-2
化学式
C10H15N2*Cl
mdl
——
分子量
198.695
InChiKey
HDJBTCAJIMNXEW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.27
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    16.1
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    nicotinium hydrochloride 、 mercury dichloride 以 乙醇 为溶剂, 生成 nicotine*HCl*3HgCl2
    参考文献:
    名称:
    Volansky, N., Diss. Bern 1897
    摘要:
    DOI:
  • 作为产物:
    描述:
    (+/-)-尼古丁盐酸 作用下, 以 为溶剂, 生成 nicotinium hydrochloride
    参考文献:
    名称:
    [EN] NICOTINE DERIVATIVES AND METHODS OF USE
    [FR] DÉRIVÉS DE NICOTINE, ET PROCÉDÉS POUR LEUR UTILISATION
    摘要:
    本发明提供了一种化合物,所选自组中包括L-尼古丁(X1)(X2)和D-尼古丁(X1)(X2),或其药学上可接受的盐,其中(i)Χ1和X2各自独立地是药学上可接受的阴离子或空集;(ii)Χ1和X2不能同时为空集。本发明还提供了相关的组合物,以及治疗通过尼古丁治疗合理地认为能够改善的疾病的方法。
    公开号:
    WO2015183530A1
点击查看最新优质反应信息

文献信息

  • [EN] NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES<br/>[FR] SELS, CO-CRISTAUX, ET COMPLEXES DE CO-CRISTAUX DE SELS DE NICOTINE
    申请人:REYNOLDS TOBACCO CO R
    公开号:WO2015183801A1
    公开(公告)日:2015-12-03
    The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
    该发明提供了某些尼古丁盐、共晶和盐共晶,并提供了某些尼古丁盐的新颖多形态形式。具体来说,描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸结合的尼古丁盐,以及尼古丁4-乙酰氨基苯甲酸、尼古丁吉替酸和尼古丁1-羟基-2-萘酸的结晶多形态形式。该发明还提供了制备和表征这些尼古丁盐、共晶和盐共晶以及其多形态形式的方法。此外,还提供了含有尼古丁盐、共晶和/或盐共晶的烟草制品,包括吸烟物品、无烟烟草制品和电子吸烟物品。
  • NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES
    申请人:R.J. Reynolds Tobacco Company
    公开号:US20150344456A1
    公开(公告)日:2015-12-03
    The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.
    本发明提供了某些尼古丁盐、共晶、盐共晶,并提供了某些尼古丁盐的新型多晶形式。具体而言,本发明描述了与粘酸、3,5-二羟基苯甲酸和2,3-二羟基苯甲酸共晶的尼古丁盐,以及尼古丁4-乙酰氨基苯甲酸盐、尼古丁吉替酸盐和尼古丁1-羟基-2-萘酸晶体多晶形式。本发明进一步提供了制备和表征这种尼古丁盐、共晶和盐共晶及其多晶形式的方法。此外,本发明还提供了含有尼古丁盐、共晶和/或盐共晶的烟草产品,包括吸烟物品、无烟烟草产品和电子吸烟物品。
  • Nicotine preparation
    申请人:ADVANCED TOBACCO PRODUCTS, INC.
    公开号:EP0148749A2
    公开(公告)日:1985-07-17
    ® This invention provides a nicotine preparation having utility in combination with dispensing devices. Specifically, the nicotine preparation of this invention includes nicotine, a nicotine enhancing material, an organic acid and a volatile carrier. Alternate embodiments of the invention include flavoring material and/or water.
    本发明提供了一种尼古丁制剂,可与分配装置结合使用。 具体而言,本发明的尼古丁制剂包括尼古丁、尼古丁增强材料、有机酸和挥发性载体。 本发明的其他实施方案包括调味材料和/或水。
  • Tobacco substitute
    申请人:UNIVERSITY OF UTAH RESEARCH FOUNDATION
    公开号:EP0745380A2
    公开(公告)日:1996-12-04
    The present invention relates generally to a ciagrette substitute for administering a dose of nicotine. More specifically, the present invention is directed to a nicotine-containing dosage-form comprising a holder member which may be used as part of an effective smoking cessation program or in situations where smoking is undesirable or not permitted. The dosage form is configured as a dosage form having a nicotine-containing composition attached to a holder member. Nicotine is released from the dosage form and absorbed through the intra-oral mucosal surfaces as the nicotine-containing composition releases nicotine within a user's mouth. The holder member facilitates insertion and removal of the dosage form into and out of a user's mouth. The user can selectively insert and remove the dosage form as desired to selectively control the release of nicotine. In addition, the user can insert and remove the dosage form in a manner which meets the user's psychological need or desire for ritualistic oral stimulation similar to cigarette smoking.
    本发明总体上涉及一种用于给药尼古丁剂量的咀嚼替代物。更具体地说,本发明涉及一种含有尼古丁的剂型,该剂型包括一个支架部件,可用作有效戒烟计划的一部分,或在不希望或不允许吸烟的情况下使用。该剂型被配置为一种剂型,其含尼古丁的组合物附着在支架部件上。当含尼古丁的组合物在使用者口腔内释放尼古丁时,尼古丁从剂型中释放出来并通过口腔内粘膜表面被吸收。夹持件便于将剂型插入和取出使用者的口腔。使用者可以根据需要选择性地插入和取出剂型,以选择性地控制尼古丁的释放。此外,使用者还可以根据自己的心理需要或愿望,插入和取出药剂,以获得类似于吸烟的口腔刺激。
  • Orally Dissolving Films
    申请人:Glaxosmithkline LLC
    公开号:EP2446881A1
    公开(公告)日:2012-05-02
    Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.
    本文公开了可在口腔中快速释放活性剂的快速溶解口服膜制剂,特别是含有尼古丁活性成分的快速溶解口服膜,这种口服膜可实现良好的经颊囊吸收,并可缓解人们对尼古丁的渴望。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-